PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-65.77%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-6.04%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-65.74%
Negative net income growth while AXSM stands at 62.55%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-47.67%
Negative EPS growth while AXSM is at 53.85%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-53.82%
Negative diluted EPS growth while AXSM is at 53.85%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
12.14%
Slight or no buybacks while AXSM is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
7.50%
Slight or no buyback while AXSM is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
-13.29%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-13.04%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-24856.69%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-19589.97%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
63.13%
Positive 3Y OCF/share CAGR while AXSM is negative. John Neff might see a big short-term edge in operational efficiency.
-19587.84%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-19245.92%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
62.10%
Positive short-term CAGR while AXSM is negative. John Neff would see a clear advantage in near-term profit trajectory.
30196.53%
Positive growth while AXSM is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
5954.03%
Positive 5Y equity/share CAGR while AXSM is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
827.17%
Positive short-term equity growth while AXSM is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6.14%
Asset growth well under 50% of AXSM's 699.60%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
-14.41%
We have a declining book value while AXSM shows 1361.12%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-8.17%
Our R&D shrinks while AXSM invests at 44.84%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
28.86%
SG&A declining or stable vs. AXSM's 89.54%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.